CD8A and neoplasm: Reports found that intratumoral low-dose ADU-S100 (MIW815), one of the synthetic CDNs for STING activation, induced local activation of tumor-specific CD8+ T cells for durable anti-tumor immunity and their combination with ICBs resulted in better anti-tumor effects in a poorly immunogenic tumor model [138].